Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Neurology

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy

NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of […]

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy
3 months ago
Share

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials

TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab […]

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials
3 months ago
Share

Kintara Therapeutics Presents Interim Data from Two Phase 2 Trials of VAL-083 for the Treatment of Glioblastoma Multiforme

Kintara Therapeutics  announced interim data on its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM).  […]

Kintara Therapeutics Presents Interim Data from Two Phase 2 Trials of VAL-083 for the Treatment of Glioblastoma Multiforme
4 months ago
Share

Despite Failing to Reach Endpoint in Phase 3 ALS Study, Brainstorm Plans to Move Forward with Development of NurOwn Stem Cells

Brainstorm Cell Therapeutics reported topline results from a Phase 3 trial evaluating NurOwn (MSC-NTF cells) as a treatment for Amyotrophic […]

Despite Failing to Reach Endpoint in Phase 3 ALS Study, Brainstorm Plans to Move Forward with Development of NurOwn Stem Cells
4 months ago
Share

Diabetes, Hypertension May Increase Risk of COVID-19 Brain Complications

Dr. Colbey W. Freeman and colleagues in the Perelman School of Medicine at the University of Pennsylvania looked at COVID-19 […]

Diabetes, Hypertension May Increase Risk of COVID-19 Brain Complications
4 months ago
Share

Top Neurology Investigators from Medical University South Carolina (MUSC) Drive Virtual Clinical Trial Investigating NeuroCOVID

In addition to the stages (incubation, symptomatic, early pulmonary & late pulmonary) associated with a SARS-CoV-2 infection, known as COVID-19, two […]

Top Neurology Investigators from Medical University South Carolina (MUSC) Drive Virtual Clincial Trial Investigating NeuroCOVID
4 months ago
Share

Biogen Releases Q3 Report; Development of MS Drug Opicinumab Discontinued Following Disappointing Phase 2 Data

Biogen reported its Q3 2020 financial results, highlighting that its total revenues had reached $3.3 million. However, this was a […]

Biogen Releases Q3 Report; Development of MS Drug Opicinumab Discontinued Following Disappointing Phase 2 Data
4 months ago
Share

FDA Places Hold on Voyager Therapeutics Experimental Gene Therapy for Huntington’s Disease

Voyager Therapeutics announced the FDA placed a clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01 for the […]

FDA Places Hold on Voyager Therapeutics Experimental Gene Therapy for Huntington’s Disease
5 months ago
Share

Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD

Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]

Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD
5 months ago
Share

Lilly Study Results Reveal Nearly 80% of Participants Report Relief from Headaches

Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their […]

Lilly Study Results Reveal Nearly 80% of Participants Report Relief from Headaches
5 months ago
Share

Posts navigation

Older posts
Newer posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.